AbbVie Reported GAAP Earnings, Adj Non-GAAP Earnings For Q3 Expected To Include Acquired IPR&D And Milestones Expense Of $66M On Pre-Tax Basis
Portfolio Pulse from Benzinga Newsdesk
AbbVie has reported its GAAP earnings for Q3, which are expected to include an acquired IPR&D and milestones expense of $66M on a pre-tax basis, according to an SEC filing.
October 04, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's Q3 GAAP earnings are expected to include an acquired IPR&D and milestones expense of $66M on a pre-tax basis. This could potentially impact the company's profitability.
The inclusion of a $66M pre-tax expense for acquired IPR&D and milestones in AbbVie's Q3 GAAP earnings could potentially reduce the company's profitability for the quarter. This could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100